Kite Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Kite Pharma and buy or sell other stocks, ETFs, and their options commission-free!

About KITE

Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. 

CEO
Arie S. Belldegrun, MD
CEOArie S. Belldegrun, MD
Employees
Employees
Headquarters
Santa Monica, California
HeadquartersSanta Monica, California
Founded
2009
Founded2009
Employees
Employees

KITE Key Statistics

Market cap
10.26B
Market cap10.26B
Price-Earnings ratio
-26.17
Price-Earnings ratio-26.17
Dividend yield
Dividend yield
Average volume
1.77M
Average volume1.77M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$179.95
52 Week high$179.95
52 Week low
$39.82
52 Week low$39.82

Stock Snapshot

The current Kite Pharma(KITE) stock price is $179.79, with a market capitalization of 10.26B. The stock trades at a price-to-earnings (P/E) ratio of -26.17.

On 2026-03-12, Kite Pharma(KITE) stock opened at —, reached a high of —, and a low of —.

The Kite Pharma(KITE)'s current trading volume is 0, compared to an average daily volume of 1.77M.

In the last year, Kite Pharma(KITE) shares hit a 52-week high of $179.95 and a 52-week low of $39.82.

In the last year, Kite Pharma(KITE) shares hit a 52-week high of $179.95 and a 52-week low of $39.82.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.